Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06908993 | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated(COMET) | recruiting | Phase 3 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07182682 | A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery | recruiting | Phase 3 | 360 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| 1 |
| Dec 15, 2025 |
| clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04980716 | Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 524 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07170995 | Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 3 | 460 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07178795 | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | recruiting | Phase 3 | 440 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.(OliGRAIL) | recruiting | Phase 3 | 124 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07150663 | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 134 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06417008 | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,080 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06734702 | Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 3 | 497 | Sun Yat-sen UniversityOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07052669 | Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC | recruiting | Phase 3 | 311 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07050043 | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC(LEDANG) | recruiting | Phase 3 | 123 | Dr Arvindran A/L AlagaOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05989542 | A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)(KUNPENG-2) | recruiting | Phase 3 | 136 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06980272 | SSGJ-707 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 420 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034326 | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 405 | Kong FanmingOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07016126 | D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC | recruiting | Phase 3 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06754644 | A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | recruiting | Phase 3 | 808 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | recruiting | Phase 3 | 350 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06617416 | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06674343 | Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | recruiting | Phase 3 | 144 | Peking Union Medical College HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05487391 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | recruiting | Phase 3 | 632 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06523673 | Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer(OPPRESS) | recruiting | Phase 3 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT05654454 | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | recruiting | Phase 3 | 620 | Mabscale, LLCINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT04322617 | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer(ATHENA) | recruiting | Phase 2 / Phase 3 | 1,200 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06300177 | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | recruiting | Phase 3 | 522 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | recruiting | Phase 3 | 570 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06043973 | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance | recruiting | Phase 3 | 98 | Qianfoshan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | recruiting | Phase 3 | 537 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Dec 17, 2025source: clinicaltrials